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Background: IKK can promote the ability of  
p52 to transactivate gene expression in a manner 
requiring p65. 
Results: p52 is induced by TLR3 activation and 
regulates Sp1 transcription. Sp1 promotes the 
transcription of IL-15. Both events require the 
presence of IKK and p52.    
Conclusion: p52 is a target for IKK in anti-viral 
immunity. 
Significance: This study reports a role for NFB2 
in the induction of anti-viral gene expression. 
 
SUMMARY: 
In this study we describe a previously unreported 
function for NFB2, an NFB family transcription 
factor, in antiviral immunity. NFB2 is induced in 
response to Poly(I:C), a mimic of viral dsRNA. 
Poly(I:C), acting via TLR3, induces p52-
dependent transactivation of a reporter gene in a 
manner that requires the kinase activity of IKK 
and the transactivating potential of RelA/p65. We 
identify a novel NFB2 binding site in the 
promoter of the transcription factor Sp1 which is 
required for Sp1 gene transcription activated by 
Poly(I:C). We show that Sp1 is required for IL-15 
induction by both Poly(I:C) and Respiratory 
Syncitial Virus, a response that also requires 
NFB2 and IKK. Our study identifies NFB2 as 
a target for IKK in anti-viral immunity and 
describes, for the first time, a role for NFB2 in 
the regulation of gene expression in response to 
viral infection. 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M113.469122The latest version is at 
JBC Papers in Press. Published on July 19, 2013 as Manuscript M113.469122
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INTRODUCTION: 
NFB2 (p100/p52), is a member of the NFB 
family of transcription factors, that comprises five 
mammalian members: Rel/c-Rel; RelA/p65; RelB; 
NFB1 (p50 and its precursor p105); and NFB2 
(p52 and its precursor p100). These proteins exist 
in various homo- and heterodimeric complexes 
and control many biological processes, particularly 
in inflammation and immunity (1).  There are two 
distinct NFB activation pathways termed the 
canonical and the alternative pathways. The 
canonical pathway is the better characterised 
NFB pathway. It is activated by innate immune 
receptors, inflammatory cytokines and stress 
pathways, and leads to the phosphorylation of the 
inhibitory subunit IB by IKK and IKK, 
leading to its degradation. The subsequent release 
and nuclear translocation of the p50/p65 dimer 
leads to the induction of a wide range of immune 
and inflammatory genes (1). The alternative 
pathway involves NFB2. Known activators of 
this pathway are CD40, BAFF receptor and LT- 
receptor. Activation of this pathway involves 
NFB-inducing kinase (NIK). NIK activates IKK 
which phosphorylates p100, causing p100 to be 
partially processed to produce the active p52 
subunit. Typically p52 is described as part of a 
heterodimer with RelB. This complex is essential 
for NFB2’ s role in humoral immunity and 
secondary lymphoid organogenesis.  
A third IKK, termed IKK has been described. 
IKK is activated downstream of the dsRNA 
receptors TLR3, RIG-I and MDA5 and by TLR4 
and IFN- (2, 3) and, in turn, activates the 
transcription factors IRF3, IRF7, STAT1 and p65. 
IKK has also been shown to be activated by 
Respiratory Syncitial Virus (RSV) and Influenza B 
virus (3, 4).  
We identified p52 as a binding partner for IKK in 
a yeast-two-hybrid screen and subsequently 
determined that over expression of IKK could 
promote the transactivating potential of p52 (5), 
however the functional importance of this 
interaction remains elusive. Here we report the 
uncovering of a signalling pathway activated by 
TLR3, or RSV, that involves IKK, NFB2 and 
p65. We identify a conserved binding site for p52 
on the Sp1 promoter and confirm IL-15, an anti-
viral cytokine, as a target for Sp1 on this pathway. 
Our study provides a previously undescribed 
function for both NFB2 and Sp1 in anti-viral 
immunity.  
EXPERIMENTAL PROCEDURES:  
Reagents and plasmids - LPS, (Alexis 
Corporation), Poly(I:C) and Poly(A:U) 
(Invivogen). Antibodies; p100/p52 cell signalling 
#4882, -actin Sigma-Aldrich #A1978, Sp1 
Milllipore #07-645. Oligonucleotides (Eurofins). 
Taqman probes (Applied Biosystems). FLAG-
IKK and IKK(K38A) were provided by Shizuo 
Akira (Osaka University, Japan). The TBK1-
encoding plasmid was a gift from Dr. Makato 
Nakanishi (National Institute for Longevity 
Sciences, Japan). HA-p52 was a gift from Neil 
Perkins (University of Dundee, Scotland). Gal-
luciferase reporter gene (Stratagene). The 
construction of the p52-Gal4 has been described 
(5). TRAF1, TRAF3, TRAF6, RIP1 and Nap1 
plasmids were gifts from Andrew Bowie (Trinity 
College Dublin, Ireland). The HA-p65(S536A) 
plasmid was generated from the HA-p65 plasmid 
using the QuikChange XL site-directed 
mutagenesis kit (Stratagene). 
 
Cell culture and Isolation – WT and IKK-/- 
MEFs obtained from Shizuo Akira (Osaka 
University, Japan) and HEK293 cells, HEK293 
cells stably expressing either TLR3 (HEK293-
TLR3) (Invivogen), were cultured in DMEM. WT, 
NFB2-/- and IKK-/- (Kate Fitzgerald, University 
of Massachusetts, USA) bone marrow, were 
isolated from the tibias and femurs of C57/Bl6 
mice, resulting cells were grown in MCSF 
conditioned DMEM. Human peripheral blood 
mononuclear cells (hPBMC) were isolated from 
whole blood using a Ficoll gradient and cultured in 
RPMI.  In all cases, DMEM and RPMI medium 
were supplemented with 10% fetal calf serum, 2 
mm l-glutamine, 1% penicillin/streptomycin 
solution (v/v).  Cells were plated at 1 x 105 
cells/ml, treated as described, before isolation of 
RNA or lysate for qPCR or Western blot 
respectively.  
Sp1-promoter luciferase construct- For 
construction of the Sp1-promoter- luciferase 
reporter gene, we cloned its 5’  regulatory region of 
Sp1 from -1303 nt from the translational start site 
 at N
ational U
niversity of Ireland, M
aynooth on M
ay 19, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
3 
 
(ATG) between the NheI and XhoI sites of the 
reporter luciferase vector pGL3-enhancer 
(Promega).  Progressive deletion constructs were 
generated using a common reverse primer and five 
different forward primers. The Sp1-specific 
sequences for these primers were taken from the 
EMBL-EBI AF261690 source (in uppercase, see 
below). For the forward primers these specific 
sequences were preceded by an arbitrary sequence 
(in lowercase, see below) including a NheI 
restriction site (italics). The reverse primer 
followed a similar structure but contained a XhoI 
restriction site (italics) in the arbitrary sequence. 
The numbers indicated after the primer sequences 
correspond to the distance in nt from the 5′-end of 
the sequence in uppercase to the translational start 
site. 
For 5’  
tcaagtcaggctagcTTGCTTTATGCATAGGCGGT-3’  
(-1303) 
For 5’  
tcaagtcaggctagcCGGATTCTGGTTGGCCGTTGT-3’  
(-477) 
For 5’  
tcaagtcaggctagcCTATCAAAGCTTTGCCTATCC-3’  
(-443) 
For 5’   
tcaagtcaggctagcGGGAGCCCGCCTGCCGGTTG -3’  
(-415) 
For 5’   
tcaagtcaggctagcTCCTTCCAAGCCAATCATCTCC-3’  
(-388) 
for 5’   
tcaagtcaggctagcGCTCCCGCCCATCTTCACTTC -3’  
(-365) 
Rev 5’  
cagtgctgcctcgagGCTCAAGGGGGTCCTGTCCGG 
3’  (-20) 
 
Transfection-based Reporter Gene Assays – 
Cells were transfected with GeneJuice transfection 
reagent (Novagen, Madison, WI) with a total 
amount of 350–400g/well containing 150ng of p-
55UASGLuc and 50 ng of p52-Gal4 fusion 
construct (MEFs) or with a total of 250ng of DNA 
containing 100ng of p-55UASGLuc or 30ng of 
p52-Gal4 (HEK293s). Assays also contained the 
plasmid DNA of interest, an empty vector and 
30ng of Renilla reniformis luciferase construct. 
For Sp1-promoter-luciferase assays, HEK293 cells 
were transfected with a total amount of 220ng of 
DNA/well comprising 80ng of reporter construct, 
the plasmid DNA of interest, 40ng of R. reniformis 
luciferase construct, and empty vector. Cell 
extracts were monitored 24–36h post-transfection 
for firefly luciferase activity following standard 
protocols with values were normalized for 
transfection efficiency with R. reniformis 
luciferase.  
RNA extraction and PCR - MEFs and BMDM or 
hPBMC were set up at 5 × 105 or 1 × 106 cells/ml, 
respectively. Cells were stimulated with Poly(I:C). 
Total RNA was extracted using the RNeasy kit 
(Qiagen). For mRNA expression analysis, cDNA 
was prepared from 20 to 100 ng/ml total RNA 
using the High-Capacity cDNA archive kit 
(Applied Biosystems). Individual mRNAs were 
monitored with the following inventoried The 
AB7900FAST platform (Applied Biosystems) was 
used for all PCR, done in triplicate. Changes in 
expression were calculated by the change in 
threshold (CT) method with Gapdh as an 
endogenous control for gene-expression analysis 
and were normalized to results obtained with 
untreated cells. TaqMan assays were from Applied 
Biosystems: mouse Sp1 assay 
(Mm00489039_m1), mouse IL-15 assay 
(Mm00434210_m1), mouse Gapdh 
(glyceraldehyde phosphate dehydrogenase) assay, 
human Sp1 assay (Hs00916521_m1), human IL-15 
assay (Hs01003713), human Gapdh assay. 
Small interfering RNA (siRNA) – The following 
RNA interference duplex was purchased from 
Qiagen, Hs_NFB2_1 FlexiTube siRNA 
SI00300965 and Allstars negative control siRNA 
(#1027281) or Dharmacon ON-TARGET plus 
siRNA Sp1 (L-026959). Following optimization, 
50 nM of siRNA was used. Human PBMC were 
transfected with siRNA using an Amaxa 
electroportator and a Cell Line Nucleofector Kit V, 
program V-01 (PBMC). 1 × 106cells/ml PBMC 
were used per point for nucleofection. Cells were 
harvested after 72 h and used for further analysis. 
Immunoblotting- MEFs and BMDM were seeded 
at 5 × 105 cells/ml, HEK293TLR3 cells were 
seeded at 1 x 105 cells/ml or hPBMC were set up 1 
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× 106 cells/ml, one day prior to stimulation with 2 
% FCS. Cells were stimulated with Poly(I:C) and 
lysed in 1 ml of low stringency lysis buffer (50 
mm HEPES, 100 mm NaCl, 1 mm EDTA, 10% 
glycerol, 0.5% Nonidet P-40, and protease 
inhibitors). Protein concentration was measured by 
Bradford and equal amounts of protein were 
separated by SDS-gel electrophoresis, transferred 
to PVDF membrane and incubated with antibody 
and visualised by autoradiography.  
Chromatin Immunoprecipitation– Genpathway, 
Inc. (CA, USA), carried out an analysis of gene 
promoters that bound to p52 using samples 
prepared from WT and IKK KO MEFs according 
to their instructions. Briefly, MEFs were set up at 
5 x 105 cell/ml. A final volume of 1% 
formaldehyde was added directly to existing 
media, incubated for 15 min. 1/20 volume of 2.5 
M glycine was then added to each flask and 
allowed to set at room temperature for 5 min. Cells 
were scraped, washed in PBS and sent on dry ice 
to Genpathway. BMDMs were set up at 5 x 105 
cell/ml, media was removed, replaced with PBS 
and fixed by adding Final concentration of 1% 
Formaldehyde to each culture dish. Flasks were 
incubated for 10 min at room temperature. 1/20 
volume of 2.5 M glycine was then added to each 
flask and allowed to set at room temperature for 5 
min. Primary antibody. Anti-p52 (Abcam #7972), 
anti-p50 (Millipore #06-886) and anti-p65 (Santa 
Cruz (F-6) sc-8008) were determined to give the 
best ChIP results. Quantitative RT-PCR was 
carried out using primers for either Sp1-promoter 
or -actin promoter as indicated. Data are 
presented as % of input. 
Affinity Purification with Biotinylated 
oligonucleotides - HEK293 cells were seeded at 1 
x 105 cell/ml and incubated overnight. Cells were 
then transfected with either 2 g of HA-p52 (five 
plates) or an empty vector control (five plates). 24 
h later cells were lysed in 100l of 
Oligonucleotide Buffer (ONB) (25mM TRIS, 
50mM EDTA, 5% glycerol, 5 mM NaF, NP40 1%, 
1mM DTT, 150 mM NaCl and protease- and 
phosphatise- inhibitors) pooled and snap frozen. 
Samples were then thawed on ice and diluted with 
a further 4.5 ml of ONB without NaCl, a 50 l 
sample of lysate was kept and the remainder was 
divided into 5 tubes and incubated for 2 h with 
streptavidin-agarose beads conjugated to 
biotinylated promoter regions, termed Seq 1-5, as 
depicted in Fig. 4f. Lysates were then centrifuged 
to pellet the beads which were washed 3 times 
before 50 l of 5 x SDS sample buffer was added 
to the beads. Samples were then immunoblotted as 
indicated. 
Viral infection of BMDM- RSV long strain 
(group A) was obtained from American Type 
Culture Collection (Manassas, VA), and 
propagated in HEp-2 cells with serial plaque 
purifications to reduce defective-interfering 
particles (6). WT and NFkB2 deficient BMDM 
were plated in 6-well (3x106 cells per well) tissue 
culture plates.  Macrophages were infected with 
RSV (multiplicity of infection = 2) or treated with 
medium alone and incubated at 37°C for the 
indicated times. 
RESULTS: 
Poly(I:C) promotes p52-driven transactivation in 
an IKK- and p65-dependent manner. Having 
previously identified p52 as a protein that interacts 
with IKK; and furthermore, showing that IKK  
promotes transactivation by p52  (5), we wished to 
probe the functional relevance of this interaction. 
Given the anti-viral role of IKK, we chose to test 
whether dsRNA analogue P(I:C) could promote 
p52-mediated transactivation. We co-transfected 
HEK293-TLR3 cells with a plasmid encoding full-
length p52 fused to the DNA-binding-domain 
(DBD) of Gal4 (p52-Gal4) and a Gal4-driven 
luciferase construct. Fig.1A shows that increasing 
concentrations of dsRNA analogues P(I:C) and 
P(A:U) promote p52-driven transactivation. Since 
P(A:U) is a dsRNA analogue only recognised by 
TLR3 (7) and P(I:C) and P(A:U) both promoted 
p52-driven transactivation to almost identical 
levels, the implication is that TLR3, and not the 
cytosolic RIG-1-like receptors, promote p52-
driven transactivation. Having previously 
identified IKK and p65 in a complex with p52 
(5), we next examined whether IKK and/or p65 
mediates P(I:C)-inducible p52- driven 
transactivation. P(I:C) failed to promote p52-
driven transactivation in IKK-/- MEFs or p65-/- 
MEFs compared with WT MEFs (Fig.1B). These 
MEF strains were responsive to TLR3 ligation as 
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demonstrated by comparable levels of P(I:C) 
inducible phosphorylation of p38 (not shown). We 
next determined whether the kinase activity of 
IKK was required for P(I:C)-inducible 
transactivation by p52. As shown in Fig. 1C, 
P(I:C) promoted p52-driven transactivation to ~5-
fold over control, whereas a kinase dead form of 
IKK (IKKK38A) inhibited this induction, 
presumably acting as a dominant negative 
inhibitor.  
Of the five NFB family members, only c-Rel, p65 
and RelB have transactivating potential (9).  p50 
and p52 are DNA binding subunits, and are unable 
to transactivate gene expression on their own. 
Since we and others have shown that p52 interacts 
with p65 (5, 10), we next tested whether p65 was 
the transactivation partner for p52 downstream of 
P(I:C). Even small amounts of p65 could strongly 
drive p52-dependent transactivation, and this 
ability of p65 to induce p52 transactivation was 
substantially impaired when the serine residue at 
position 536 in p65 was mutated to an alanine 
(p65S536A) (Fig.1D). Phosphorylation of p65 at 
position S536 is known to be very important for 
the efficient transactivating potential of p65 in 
response to many ligands, and IKK is known to 
phosphorylate S536 in response to P(I:C) (8-11). 
We next investigated whether p65 could induce 
p52-dependent transactivation in IKK-/- MEFs. As 
shown in Fig.1E, p65 induced p52-transactivation 
in WT MEFs but this induction was substantially 
impaired in IKK-/- MEFs, indicating that p65 
requires IKK to confer its transactivation 
potential to p52. IRF3, another transcription factor 
with transactivating potential, is activated 
downstream of P(I:C) and phosphorylated by 
IKK (10, 12). However, IRF3 is unable to 
mediate transactivation by p52 in HEK293-TLR3 
cells (Fig.1F). Together, these results imply that 
P(I:C) activates IKK that, in turn, mediates p65 
transactivation of the p52-dependent reporter gene, 
likely by phosphorylating p65 at position S536 
(11-14).  
We further investigated whether components of 
the TLR3 signalling pathway could promote p52-
driven transactivation. Fig.1G-I demonstrates that 
TRIF, when over-expressed, can strongly induce 
p52-driven transactivation; TRAF3, TRAF6 and 
RIP1, IKK and TBK1, all of which are known to 
be downstream of TRIF (13, 14), can promote 
p52-dependent transactivation in a dose-dependent 
manner, whereas TRAF1 and the IKK/TBK1 
adaptor NAP1 cannot. To determine whether 
TRIF-induced p52 transactivation is mediated by 
IKK, we compared the ability of TRIF to drive 
p52 transactivation in WT and IKK-/- MEFs (Fig 
1J). IKK is required for TRIF-induced p52 
transactivation, as TRIF was unable to induce p52 
transactivation in IKK-/- MEFs (Fig.1J). 
All of these data pointed to p52 as an important 
target for TLR3 signaling and we further 
confirmed this by demonstrating that expression 
levels of both p100 and p52 were induced by 
P(I:C) in a dose-dependent manner (Fig. 1K). 
p52 binds to the promoter of the Sp1 gene to 
activate its transcription - Having shown that p52 
is induced and activated by P(I:C), we next 
interrogated the gene promoters that were bound 
by p52 in response to P(I:C). We carried out ChIP 
analysis to determine genes that p52 might bind to.  
This was carried out commercially by Genpathway 
Inc. who revealed that p52 binds to an enhancer 
sequence in the Sp1 gene promoter in the region 
shown in Fig.2A. We next carried out ChIP 
analysis comparing WT and IKK-/- BMDMs 
treated with P(I:C) for 3 h. As shown in Fig.2B, 
there was no difference between WT and IKK-/- 
cells in the basal binding of p52 to the Sp1 
promoter. However P(I:C) induced a five-fold 
increase in binding of p52 to the Sp1 promoter  in 
WT BMDMs and this was abrogated in  IKK-/- 
BMDMs. We also investigated the binding of the 
NFB subunit p65, to the Sp1 promoter. p65 
binding to the promoter was significantly 
increased 2 fold in response to P(I:C). Binding of 
p65 to the TNF promoter was measured as a 
positive control for p65 binding (not shown). p52 
binding was again evident in the P(I:C)-treated 
cells (Fig. 2C).  
To examine this region further and locate the DNA 
element important for the transcriptional 
regulation of the Sp1 gene by p52, a series of 5′-
deletion promoter constructs were generated by 
PCR and cloned into the promoterless pGL3-
enhancer luciferase reporter vector. The resulting 
constructs, contain 5′-flanking regions from −20 to 
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−474, -443, -412, -385 and -362 relative to the 
translational start codon.. HEK293 cells were 
transfected with the deletion constructs in 
conjunction with increasing amounts of plasmid 
expressing HA-p52. A 4-fold increase in activity 
was induced by co-transfection of pGL3-474 with 
HA-p52, compared with that of pGL3-474 alone 
(Fig.2D). Deletion to -443 abolished this activity, 
which was also abolished in all the other 
constructs (not shown). These results demonstrate 
that the Sp1 promoter is activated by p52 in the 
region of sequence between -443 and -474 nts 
relative to the start site. We next employed an 
oligo-pulldown assay to assess if P(I:C) could 
induce the binding of p52 and p65 to this region of 
the promoter (-443 to -474). This is clearly the 
case, since P(I:C) specifically induced the binding 
of both p52 (second panel) and p65 (third panel) 
but not p100 (top panel) or p50 (bottom panel) to 
the oligonucleotide sequence indentified from the 
Sp1-luciferase assay (Fig. 2E). Interestingly the 
bound form of p65 appears to be in a 
phosphorylated state, since we were also able to 
weakly detect P-p65S536 in the induced complex 
(fourth panel).  
We further defined the p52 binding site using this 
assay. Overexpressed HA-p52 binds to the 
oligonucleotide consisting of the sequence from -
434 to -472 (Fig 2F, Seq 1, lane 2), and also to the 
sequences from -443 to -472 (Seq 2, lane 4), from 
-452 to -472 (Seq 3, lane 6) and from -434 to -462 
(Seq 4, lane 8). However, HA-p52 does not bind to 
the oligonucleotide consisting of the sequence 
from -434 to -452 (Seq 5, lane 10) (Fig. 2F). 
Sequence 5 differs from the sequences 1-4 in that 
it lacks the sequence GGCCGTTGTT. 
Interestingly, this area in the promoter of Sp1 is 
conserved among species (Fig.2G). This identifies, 
for the first time, GGCCGTTGTT as a binding site 
for p52. 
Having demonstrated that p52 binds to the Sp1 
promoter we next tested the functional 
consequences of this response. As shown in Fig. 
2H.  P(I:C) induced the expression of Sp1 mRNA 
in WT BMDMs whereas this effect was not 
observed in either IKK-/- or NFB2-/- BMDMs. 
To determine whether this effect could be seen in 
human cells, siRNA directed against NFB2, or a 
non-targeting control, were transfected into PBMC 
and Sp1 induction was measured. P(I:C) induced 
Sp1 expression in control cells, this induction was 
lost in NFB2-knockdown cells (Fig.2I).  
Sp1, IKK and NFB2 regulate IL-15 gene 
transcription - We next determined target genes 
for Sp1 that might be relevant to the anti-viral 
response. The promoter of IL-15, a pro-
inflammatory, anti-viral cytokine, was strongly 
predicted to be regulated by Sp1. IL-15 is known 
to be induced by P(I:C) and by viral infection (16, 
17). We hypothesized that a P(I:C)-inducible gene 
regulated by Sp1 should not be induced in either 
IKK or NFB2 knockout cells. To validate IL-15 
as a Sp1 target gene, human PBMC were 
transfected with siRNA directed against Sp1 or a 
non-targeting control and IL-15 induction was 
measured. P(I:C) caused an increase in the level of 
IL-15 mRNA over time that was lost in cells 
deficient in Sp1 (Fig. 3A). Importantly Sp1 knock 
down did not reduce the ability of the PBMCs to 
induce IL-6 (not shown) or RANTES, which was 
in fact increased upon Sp1 knock down (Fig. 3B). 
These are Sp1-independent, P(I:C)-inducible 
genes, indicating specificity in the IL-15 
observation. This effect was confirmed 
pharmacologically in PBMC pretreated with 1 M 
Mithramycin A (MMA), an Sp1 inhibitor. P(I:C) 
caused a ~5 fold increase in the level of IL-15 
mRNA over basal levels after 8 h. This effect was 
inhibited by pretreatment with MMA (Fig.3C).  
Following this we measured the IL-15 transcript in 
response to P(I:C) in WT, NFB2-/- and IKK-/- 
BMDMs. IL-15 transcript levels increased 60-fold 
in WT BMDMs after 8 h Poly(I:C) treatment, 
whereas a marked inhibition of this response was 
observed in both NFB2-/- and IKK-/- BMDMs 
(Fig.3D). This dependency of P(I:C)-induced IL-
15 levels on NFB2 was confirmed in human 
PBMC, where no increase was observed in PBMC 
transfected with siRNA targetted against NFB2 
(Fig. 3E). These data therefore implicate IKK, 
NFB2 and Sp1 in the induction of IL-15 by 
P(I:C).  
RSV infection fails to upregulate Sp1 and IL-15 
transcripts in both IKK and NFB2 knockout 
BMDMs - Finally we examined whether this 
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pathway was important for induction of IL-15 by a 
virus. RSV is recognised by TLR3 during infection 
(18, 19) and is a powerful inducer of IL-15 (16). 
We infected WT, IKK-/- and NFB2-/- BMDMs 
with RSV (moi =2) for 4, 8 or 24 h and measured 
Sp1 mRNA levels. As shown in Fig.4A left hand 
panel, Sp1 transcript was induced 10 fold after 4 h 
RSV infection in WT BMDM. Conversely no 
induction of Sp1 was observed in IKK-/- BMDMs 
after RSV infection (Fig.4A, right hand panel). 
Similarly no Sp1 was inducible by RSV infection 
in NFB2-/- BMDMs (Fig.4B). As shown in 
Fig.5C left hand panel, IL-15 is induced by RSV 
in WT BMDMs. However this induction of IL-15 
is completely abrogated in RSV-infected IKK-/- 
BMDMs (Fig.4C, right hand panel). Similarly, 
RSV induced IL-15 is abrogated in NFB2-/- 
BMDMs (Fig.4D, right hand panel). In order to 
determine the specificity of the effect of NFB2 
and IKK on RSV-inducible IL-15, we measured 
levels of IFN and IL-12p40, two further RSV 
inducible genes, and found that neither NFB2 or 
IKK deficiency reduced the levels of these 
cytokines in response to RSV infection (Fig.4E-
H).  These results, therefore, indicate that similar 
to P(I:C), RSV infection will trigger a pathway 
involving NFB2, activated by IKK, leading to 
upregulation of Sp1 and induction of IL-15, which 
could be  critical for anti-viral immunity 
DISCUSSION: 
In the NFB field, the majority of studies 
concerned with infection and inflammation have 
centred on the canonical NFB pathway, whereas 
NFB2 is better known for its functions in 
lymphoid organogenesis and humoral immunity 
(20).  
In this study, we present a novel inducer and 
activator of NFB2 in the form of Poly(I:C), that 
acts via TLR3.  A few studies have identified an 
indirect role for NFB2 in host defense. With 
respect to viral immunity, RSV infection has been 
shown to induce the release of p65 from p100/p65 
complexes (21). However, the elucidation of genes 
potentially regulated by NFB2 in the host 
response to infection has been unexplored. 
Sp1 was identified as a target gene for p52 in 
response to Poly(I:C) through ChIP analysis. Sp1 
is a transcription factor, first identified based on its 
ability to interact with the GC-rich motif of simian 
virus 40 regulatory sequences (22). Sp1 plays a 
critical role in many diverse cellular events such as 
cell growth (23), differentiation (24), apoptosis 
(23), angiogenesis (25), and viral latency (26), by 
regulating the expression of other genes. Sp1 was 
once thought to serve mainly as a constitutive 
activator of housekeeping genes. However, 
growing evidence indicates that various post-
translational modifications can influence the 
transcriptional activity and stability of Sp1, 
making it a transcription factor responsive to 
extracellular signals.  
Sp1 associates physically and cooperates 
functionally with several cellular transcriptional 
activators and also with several viral regulatory 
proteins including the HIV-1 regulatory protein, 
Tat (27) and HCMV’s IE gene products (28). 
These associations determine the level of Sp1-
mediated, viral or host gene transcription (29, 30). 
Furthermore, Sp1 regulated elements are found in 
the promoters of various viruses such as HIV-1 
(26), SV40 (22), HSV-1 (31), HCMV (32) and 
EBV (33). The fact that recognition elements of 
Sp1 are frequently found in the promoters of 
various viral genes and, furthermore, that viral 
regulatory proteins associate with Sp1 to affect its 
transactivating potential, implies that viruses have 
hijacked the host response to infection, in the form 
of increased Sp1 availability, to their own 
advantage. This indicates that Sp1 induction upon 
viral infection is probably a common event during 
host defence. However, although there is an 
abundance of circumstantial evidence indicating a 
role for Sp1 in host defence against viral infection, 
only one study has demonstrated a functional role 
for Sp1 in the antiviral response in the skin to 
Vaccinia virus through its regulation of OAS2 
expression (34).  Therefore, we considered Sp1 a 
valid target for further investigation.  
The identification of sequences to which NFB 
dimers bind and effect gene expression in a dimer-
specific manner is under intense investigation.  
Active NFB dimers bind to specific DNA sites in 
the promoters of target genes that are collectively 
known as B-sites (35). The classical B-sites 
follow the 5’ -GGGRNWYYCC-3’  consensus 
(R=purine, Y=pyrimidine, W=A or T and N= any 
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nucleotide), however it has been reported that the 
p52/RelB heterodimer binds to and activates a 
unique class of B-site with the consensus 5’ -
RGGAGAYTTR-3’  (R=A or G and Y= C or T). 
This consensus sequence is present in the 
promoters of chemokines involved in lymphoid 
development and the maintenance of the splenic 
architecture (36). With increasing numbers of 
NFB-regulated DNA target sites being 
discovered, the diversity of these B-sequences is 
becoming more apparent, with even the stringency 
of the GGG and CC core sequences called into 
question (37). Our study has identified a 
previously undescribed B-site 5’ - 
GGCCGTTGTT -3’  targeted by p52/p65 in the 
promoter of the Sp1 gene in the region between -
474 and -443 nts from the translational start site.  
Functionally, we have demonstrated that Sp1 
mRNA and protein levels increase upon P(I:C) 
treatment and that this increase is not observed in 
cells lacking either IKK, p65 or NFB2. We 
chose IL-15 as a possible candidate when 
considering what target genes might be regulated 
by Sp1. The role of IL-15 in host defense against 
viral infections is well documented, and it is 
known to be induced in response to numerous 
viruses including RSV (16, 38). IL-15 is a potently 
pro-inflammatory cytokine with a diverse range of 
immune-regulatory functions (39). The IL-15 gene 
promoter is also predicted to have two Sp1 sites 
(40). We confirmed that IL-15 gene expression 
required the presence of active Sp1 in PBMC in 
response to P(I:C) and that its induction required 
both IKK and NFB2. 
Finally, we examined the role of IKK and NFB2 
in a viral infection model. RSV is a major human 
respiratory pathogen and the leading cause of 
lower respiratory tract infection in infants 
worldwide (19). RSV is a ssRNA virus, however it 
makes dsRNA during its replication cycle and it 
has been reported that TLR3 mediates 
inflammatory cytokine and chemokine production 
in response to RSV infection (19, 41).       
Knocking out IKK alone completely abrogates 
any Sp1 or IL-15 gene expression in response to 
RSV. It is known that IKK phosphorylates both 
IRF3 and p65 in response to RSV to increase the 
transactivation potential of these transcription 
factors (4, 42). As the IL-15 promoter has also 
been shown to have a virus-inducible region, 
encompassing an IRF-element (IRF-E) and a 
consensus NFB motif (43), the lack of IL-15 gene 
expression in response to RSV in IKK- deficient 
BMDMs could conceivably be due to the 
insufficient transactivation of p65 and IRF3. 
However, we believe this is unlikely as other 
kinases can act in place of IKK in this role, most 
notably TBK1 and IKK (8, 12). In addition, we 
observed that BMDMs that lack NFB2 also fail 
to upregulate IL-15 gene expression in response to 
either P(I:C) or RSV, suggesting that IKK acts 
upstream of NFB2 in our system. The mechanism 
of P(I:C)- and RSV-induced IL-15 expression is 
likely due to the ligation of TLR3, which both 
activates IKK and induces p52. p52 then binds 
the promoter of Sp1 with p65, inducing its 
expression, Sp1 then binds the promoter of IL-15, 
upregulating its expression. We were unable to test 
RSV in vivo in NFB2-/- mice since they are 
severely immunocompromised due to defective 
lymphoid organogenesis (20, 44).   
The number of genes regulated by IKK in a non-
redundant manner are very few (3), so it is of 
interest that we report two new genes to add to this 
list, i.e., Sp1 and IL-15. Similarly, the number of 
genes known to be regulated by NFB2 is small in 
number and relate only to lymphoid 
organogenesis, humoral immunity, and DNA 
damage (36, 45, 46). Considering the abundance of 
functions of IL-15 (41), we therefore present a role 
for NFB2 as a key regulator of anti-viral 
immunity. Furthermore, TLR3 signalling is 
activated by viral, bacterial and parasite-derived 
dsRNA or by host-derived mRNA (47). Therefore, 
it is conceivable that NFB2 alone or in 
conjunction with Sp1 will be found to play a role 
in host defence against a broader range of 
infectious agents and also in autoimmunity.    
 at N
ational U
niversity of Ireland, M
aynooth on M
ay 19, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
9 
 
 REFERENCES: 
1. Vallabhapurapu S & Karin M (2009) Regulation and function of NF-kappaB transcription factors 
in the immune system. Annu Rev Immunol 27:693-733. 
2. Clement JF, Meloche S, & Servant MJ (2008) The IKK-related kinases: from innate immunity to 
oncogenesis. Cell Res 18(9):889-899. 
3. Tenoever BR, et al. (2007) Multiple functions of the IKK-related kinase IKKepsilon in 
interferon-mediated antiviral immunity. Science 315(5816):1274-1278. 
4. Bao X, et al. (2010) IKKepsilon modulates RSV-induced NF-kappaB-dependent gene 
transcription. Virology 408(2):224-231. 
5. Wietek C, et al. (2006) IkappaB kinase epsilon interacts with p52 and promotes transactivation 
via p65. J Biol Chem 281(46):34973-34981. 
6. Gupta CK, Leszczynski J, Gupta RK, & Siber GR (1996) Stabilization of respiratory syncytial 
virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of 
RSV vaccines and immune globulin. Vaccine 14(15):1417-1420. 
7. Wang L, et al. (2002) Noncoding RNA danger motifs bridge innate and adaptive immunity and 
are potent adjuvants for vaccination. J Clin Invest 110(8):1175-1184. 
8. Buss H, et al. (2004) Constitutive and interleukin-1-inducible phosphorylation of p65 NF-
{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase 
(IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding 
kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated 
factor II31-mediated interleukin-8 transcription. J Biol Chem 279(53):55633-55643. 
9. Doyle SL, Jefferies CA, Feighery C, & O'Neill LA (2007) Signaling by Toll-like receptors 8 and 
9 requires Bruton's tyrosine kinase. J Biol Chem 282(51):36953-36960. 
10. Fitzgerald KA, et al. (2003) IKKepsilon and TBK1 are essential components of the IRF3 
signaling pathway. Nat Immunol 4(5):491-496. 
11. Yang F, Tang E, Guan K, & Wang CY (2003) IKK beta plays an essential role in the 
phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 
170(11):5630-5635. 
12. Sharma S, et al. (2003) Triggering the interferon antiviral response through an IKK-related 
pathway. Science 300(5622):1148-1151. 
13. Gauzzi MC, Del Corno M, & Gessani S (2010) Dissecting TLR3 signalling in dendritic cells. 
Immunobiology 215(9-10):713-723. 
14. Su X, et al. (2006) TNF receptor-associated factor-1 (TRAF1) negatively regulates Toll/IL-1 
receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling. Eur J 
Immunol 36(1):199-206. 
15. Shinkura R, et al. (1999) Alymphoplasia is caused by a point mutation in the mouse gene 
encoding Nf-kappa b-inducing kinase. Nat Genet 22(1):74-77. 
16. Ennaciri J, Ahmad R, & Menezes J (2007) Interaction of monocytic cells with respiratory 
syncytial virus results in activation of NF-kappaB and PKC-alpha/beta leading to up-regulation of 
IL-15 gene expression. J Leukoc Biol 81(3):625-631. 
17. Mattei F, Schiavoni G, Belardelli F, & Tough DF (2001) IL-15 is expressed by dendritic cells in 
response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell 
activation. J Immunol 167(3):1179-1187. 
18. Liu P, et al. (2007) Retinoic acid-inducible gene I mediates early antiviral response and Toll-like 
receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J Virol 
81(3):1401-1411. 
 at N
ational U
niversity of Ireland, M
aynooth on M
ay 19, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
10 
 
19. Rudd BD, Burstein E, Duckett CS, Li X, & Lukacs NW (2005) Differential role for TLR3 in 
respiratory syncytial virus-induced chemokine expression. J Virol 79(6):3350-3357. 
20. Caamano JH, et al. (1998) Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal 
splenic microarchitecture and B cell-mediated immune responses. J Exp Med 187(2):185-196. 
21. Liu P, Li K, Garofalo RP, & Brasier AR (2008) Respiratory syncytial virus induces RelA release 
from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-
I{middle dot}NF- kappa B-inducing kinase signaling pathway. J Biol Chem 283(34):23169-
23178. 
22. Dynan WS & Tjian R (1983) The promoter-specific transcription factor Sp1 binds to upstream 
sequences in the SV40 early promoter. Cell 35(1):79-87. 
23. Kaczynski J, Cook T, & Urrutia R (2003) Sp1- and Kruppel-like transcription factors. Genome 
Biol 4(2):206. 
24. Opitz OG & Rustgi AK (2000) Interaction between Sp1 and cell cycle regulatory proteins is 
important in transactivation of a differentiation-related gene. Cancer Res 60(11):2825-2830. 
25. Mazure NM, Brahimi-Horn MC, & Pouyssegur J (2003) Protein kinases and the hypoxia-
inducible factor-1, two switches in angiogenesis. Curr Pharm Des 9(7):531-541. 
26. Jones KA, Kadonaga JT, Luciw PA, & Tjian R (1986) Activation of the AIDS retrovirus 
promoter by the cellular transcription factor, Sp1. Science 232(4751):755-759. 
27. Loregian A, et al. (2003) The Sp1 transcription factor does not directly interact with the HIV-1 
Tat protein. J Cell Physiol 196(2):251-257. 
28. Xu J & Ye L (2002) Human cytomegalovirus IE2 protein interacts with transcription activating 
factors. Sci China C Life Sci 45(6):604-612. 
29. Rossi A, et al. (2006) Human immunodeficiency virus type 1 Tat prevents dephosphorylation of 
Sp1 by TCF-4 in astrocytes. J Gen Virol 87(Pt 6):1613-1623. 
30. Yurochko AD, Mayo MW, Poma EE, Baldwin AS, Jr., & Huang ES (1997) Induction of the 
transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the 
p65 and p105/p50 NF-kappaB promoters. J Virol 71(6):4638-4648. 
31. Jones KA & Tjian R (1985) Sp1 binds to promoter sequences and activates herpes simplex virus 
'immediate-early' gene transcription in vitro. Nature 317(6033):179-182. 
32. Walker S, Hagemeier C, Sissons JG, & Sinclair JH (1992) A 10-base-pair element of the human 
immunodeficiency virus type 1 long terminal repeat (LTR) is an absolute requirement for 
transactivation by the human cytomegalovirus 72-kilodalton IE1 protein but can be compensated 
for by other LTR regions in transactivation by the 80-kilodalton IE2 protein. J Virol 66(3):1543-
1550. 
33. Howe JG & Shu MD (1989) Epstein-Barr virus small RNA (EBER) genes: unique transcription 
units that combine RNA polymerase II and III promoter elements. Cell 57(5):825-834. 
34. Bin L, et al. (2011) Specificity protein 1 is pivotal in the skin's antiviral response. J Allergy Clin 
Immunol 127(2):430-438 e431-432. 
35. Chen FE, Huang DB, Chen YQ, & Ghosh G (1998) Crystal structure of p50/p65 heterodimer of 
transcription factor NF-kappaB bound to DNA. Nature 391(6665):410-413. 
36. Bonizzi G, et al. (2004) Activation of IKKalpha target genes depends on recognition of specific 
kappaB binding sites by RelB:p52 dimers. EMBO J 23(21):4202-4210. 
37. Fusco AJ, et al. (2009) NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites 
with two distinct modes. EMBO Rep 10(2):152-159. 
38. Fawaz LM, Sharif-Askari E, & Menezes J (1999) Up-regulation of NK cytotoxic activity via IL-
15 induction by different viruses: a comparative study. J Immunol 163(8):4473-4480. 
39. Carroll HP, Paunovic V, & Gadina M (2008) Signalling, inflammation and arthritis: Crossed 
signals: the role of interleukin-15 and -18 in autoimmunity. Rheumatology (Oxford) 47(9):1269-
1277. 
 at N
ational U
niversity of Ireland, M
aynooth on M
ay 19, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
11 
 
40. Washizu J, Nishimura H, Nakamura N, Nimura Y, & Yoshikai Y (1998) The NF-kappaB binding 
site is essential for transcriptional activation of the IL-15 gene. Immunogenetics 48(1):1-7. 
41. Huang S, Wei W, & Yun Y (2009) Upregulation of TLR7 and TLR3 gene expression in the lung 
of respiratory syncytial virus infected mice. Wei Sheng Wu Xue Bao 49(2):239-245. 
42. Indukuri H, et al. (2006) Ikkepsilon regulates viral-induced interferon regulatory factor-3 
activation via a redox-sensitive pathway. Virology 353(1):155-165. 
43. Azimi N, Shiramizu KM, Tagaya Y, Mariner J, & Waldmann TA (2000) Viral activation of 
interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. 
J Virol 74(16):7338-7348. 
44. Franzoso G, et al. (1998) Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects 
in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 
187(2):147-159. 
45. Schneider G, et al. (2006) IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- 
to S-phase progression. EMBO J 25(16):3801-3812. 
46. Schumm K, Rocha S, Caamano J, & Perkins ND (2006) Regulation of p53 tumour suppressor 
target gene expression by the p52 NF-kappaB subunit. EMBO J 25(20):4820-4832. 
47. Kariko K, Ni H, Capodici J, Lamphier M, & Weissman D (2004) mRNA is an endogenous ligand 
for Toll-like receptor 3. J Biol Chem 279(13):12542-12550. 
 
ACKNOWLEDGEMENTS: 
The authors would like to thank Science Foundation Ireland for funding this work through the 
Immunology Research Cluster (S.F.I. 07/SRC/B1144). The work carried out in the SNV laboratory was 
funded by the NIH (NIH AI18797 (SNV)). The work in JHC laboratory was funded by the EU FP7 
INFLA-CARE collaborative research programme (Contract 223151), the Biotechnology and Biological 
Sciences Research Council (Grant BB/D018234/1) and by the School of Immunity and Infection of the 
College of Medicine of the University of Birmingham, UK. We would also like to acknowledge Meghan 
E. Pennini, for her help in isolating BMDMs from the IKK  deficient mice. We would like to 
acknowledge Adrian Bracken for his help in designing the ChIP assays.
 at N
ational U
niversity of Ireland, M
aynooth on M
ay 19, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
12 
 
FIGURE LEGENDS: 
Figure 1 Poly(I:C) induces p100 and p52 expression and p52-dependent transactivation in an IKK-and 
p65-dependent manner: (A-J) p52-dependent transactivation was assayed in all cells using 150ng of p-
55UASGLuc and 50ng of p52-Gal4 or Gal4-DBD. HEK293-TLR3 cells were (A) stimulated with 
Poly(A:U) or Poly(I:C) 24h post-transfection or left untreated (contol) and incubated for 6h, or co-
transfected with plasmid encoding (C) IKKKA (D) p65, p65S536A or EV.  (B) WT, IKK KO or p65 
KO MEFs were stimulated with P(I:C) 24h post-transfection or left untreated (control) and incubated for 
6h. (E) WT and IKK KO MEFs were co-transfected with p65 or EV as indicated. (F-I) HEK293 cells or 
(J) wildtype and IKK-/- MEFs, were co-transfected with plasmid encoding (F) IRF3, p65 (G, J) Trif, (H) 
TRAF1, TRAF3, TRAF6, RIP1, or (I) IKK, Nap1, TBK1 or with empty vector only (EV) as indicated. 
Luciferase activity was determined 24-36 h after transfection. Data are the means of three measurements, 
with error bars representing S.D. (K) HEK293-TLR3 cellswere treated with increasing doses of P(I:C) 
for 24h lysed and probed for p100/p52. Data are representative of 3 separate experiments. 
Figure 2 Poly(I:C) induces p52 and p65 to bind a previously undescribed site in the Sp1 promoter to 
drive transcription in an IKK-, p65- and NFB2-dependent manner  (A) A partial sequence of the Sp1 
promoter region -474 nts to -362 nts 5’  from the start codon. The primers used for the ChIP assay are 
underlined. (B) WT and IKK KO BMDMs were treated with P(I:C) for 3h or left untreated, after which a 
ChIP assay was performed using an anti-p52 antibody. Primers specific for promoters of Sp1 or -actin 
were designed, and binding events of p52 were measured as % of input. (C) WT BMDMs were treated 
with P(I:C) for 0, 3 and 6h, after which a ChIP assay was performed using antibodies against HA 
(control), p65 or p52, binding events were measured as % of input. Data are the means of three 
measurements with error bars representing S.D. Statistical analysis was carried out using Student T-test, 
(*) = P<0.05 (**) = P<0.001 (***) = P<0.0001. Values are representative of three separate experiments. 
(D) Sp1 promoter truncations were cloned into a pGL3 luciferase reporter vector, Sp1 promoter activity 
was assayed in HEK293 cells transfected with 80ng of pGL3 vector containing Sp1 promoter truncations  
-474 and -443 nts 5’  from the start site respectively, or with pGL3 vector alone. Cells were co-transfected 
with plasmid encoding HA-p52. Luciferase activity was determined 24h after transfection and is 
represented as fold increase in luciferase over each individual pGL3-Sp1-promoter construct EV control. 
Data are the means of three measurements, with error bars representing S.D. Values are representative of 
three independent experiments. (E) HEK293-TLR3 cells were treated with P(I:C) for 0 and 3h, lysed and 
an Oligopulldown (OPD) assay was carried out with the -472 to -434 oligo sequence, samples were 
probed for p100, p52, p65, P-p65S536 and p50. (F) An OPD assay was carried out in HEK293 cells using 
the oligonucleotide sequence from -472 to -434 5’  from the Sp1 translational start codon (seq 1) and 
truncations of this nucleotide sequence (sequences 2-5) as shown in (F, bottom panel). Cells were 
transfected with plasmid encoding either HA-p52 (+) or empty vector (-). 24h later cells were lysed, 
incubated with oligos as indicated and probed for HA (F, top panel). OPD assays are representative of 
two separate experiments. (G) Species sequence alignment of the site in the Sp1-promoter. Upstream 
regions were obtained via biomart taking the flanked regions 2500 base pairs upstream. An alignment was 
created using MUSCLE. The alignment was viewed and an image exported via Jalview. The ten central 
base pairs in the alignment are the binding site, the binding site starts -364 upstream from the gene start 
site in the human sequence. (H) WT, IKK KO and NFB2 KO BMDMs or (I) PBMCs transfected with 
either siRNA targeting NFB2 or a non-targeting control siRNA for 48h, were stimulated with P(I:C) for 
0, 4 and 8h as indicated. (H-I) Quantitative RT-PCR analysis of RNA from these cells was carried out 
with primers specific for Sp1; expression is normalised to that of GAPDH and is presented relative to that 
of untreated controls. Data are the mean of at least three separate experiments with each point assayed in 
triplicate, with error bars representing S.D.  
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Figure 3 IL-15 induction in response to Poly(I:C) requires Sp1, IKK and NFB2: (A,B,E) PBMCs were 
transfected with siRNA targeting (A, B) Sp1 (E) NFB2 or a non-targeting control siRNA for 48h,  cells 
were then stimulated with P(I:C) for 0, 4 and 8h as indicated.   (C) PBMC were pre-treated for 1h with 
1M Mithramycin A (MMA) or left untreated before stimulation with P(I:C). (D) WT, IKK-/- and NFB2-
/- BMDMs were stimulated with P(I:C) for 4, 8 and 24h or left untreated as indicated. In each case, RT-
PCR analysis of RNA was carried out with primers specific for IL-15, or RANTES as indicated; expression 
is normalised to that of GAPDH and is presented relative to that of untreated controls. Data are the mean of 
at least three separate experiments with each point assayed in triplicate, with error bars representing S.D. 
 
Figure 4 RSV infection induces both Sp1 and IL-15 in an IKK- and NFB2-dependent manner: WT, IKK 
-/- and NFB2-/- BMDMs were infected with RSV long strain (group A) (moi=2) or treated with medium for 
2, 4, 8 or 24h. Cells were lysed and RNA was extracted for RT-PCR analysis, with primers specific for 
(A,B) Sp1, or (C,D) IL-15, or (E,F) IFN, or (G,H) IL-12p40; expression is normalised to that of GAPDH 
and is presented relative to that of untreated controls. Data are representative of three separate experiments, 
with each point assayed in triplicate, with error bars representing S.D. 
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